Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy.
|
30389746 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hence, our study aims to investigate protective effect of hUSC exosome along with microRNA-16-5p (miR-16-5p) on podocytes in DN via vascular endothelial growth factor A (VEGFA).
|
31568645 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, this study was conducted to explore the effect of CaD on restoring autophagy in DKD and the possible signaling pathway between VEGF and autophagy.
|
31447680 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
DIAVIT, in particular delphinidin, alters VEGF-A splicing in type II DN, rescuing the DN phenotype.
|
30865689 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consequently, our data suggested that ORP150 levels were positively correlated with proteinuria burden via mediating VEGF in DN.
|
31028725 |
2019 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TMA is associated with low VEGF expression and end-stage renal disease in patients with diabetic nephropathy..
|
29249229 |
2018 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that glomerular LRG1 expression is increased earlier than VEGF expression under conditions of pathological angiogenesis in the early stage of diabetic nephropathy.
|
30515388 |
2018 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated the effect of Pueraria tuberosa extract (PTY-2r) on the expression of HIF-1α, VEGF and nephrin in streptozotocin (STZ) induced diabetic nephropathy (DN).
|
28648975 |
2017 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Unlike its experimental counterpart, human diabetic nephropathy is associated with diminished VEGF-A levels and experience in the oncological setting has taught us that VEGF blocking therapy can cause adverse renal effects in patients.
|
27836681 |
2017 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Serum miR-9 is a potential marker for conferring a poor prognosis in DN and associated with the levels of VEGF, PEDF and biochemical indices.
|
28667418 |
2017 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We assessed MBL levels and corresponding MBL2 genotype, together with vascular endothelial growth factor (VEGF) levels as a marker of vascular damage, in type 1 diabetes patients with diabetic nephropathy before and after simultaneous pancreas-kidney (SPK) transplantation.
|
26768002 |
2016 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The pattern of renal VEGF-A splice variants was unchanged in diabetic nephropathy and lupus nephritis and was stable throughout disease progression in acute transplant rejection and diabetic nephropathy; these results suggest renal VEGF-A splicing stability during kidney disease.
|
27598902 |
2016 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Most of these eleven genetic variants were involved in GPCR signaling and receptor binding pathways whereas four were involved in chronic kidney failure. rs833061 [OR 2.08 (95% CI 1.63-2.66)] in the VEGFA gene and rs3917887 [OR 2.04 (95% CI 1.64-2.54)] in the CCL2 gene showed the most significant association with the risk of diabetic nephropathy.
|
25280384 |
2014 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Considering the putative contribution of VEGF to T2D and its complications, we aimed to assess the effect of these VEGF-related SNPs on the risk of T2D, nephropathy and retinopathy, as well as on variation in related traits.SNPs were genotyped in several case-control studies: French and Danish T2D studies (N(cases) = 6,920-N(controls) = 3,875 and N(cases) = 3,561-N(controls) = 2,623; respectively), two French studies one for diabetic nephropathy (N(cases) = 1,242-N(controls) = 860) and the other for diabetic retinopathy (N(cases) = 1,336-N(controls) = 1,231).
|
23405237 |
2013 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry showed both increased TRPC6 channel protein and VEGF receptor type 2 (VEGFR-2) protein in podocytes from patients with diabetic nephropathy compared to control subjects.
|
21868397 |
2012 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The involvement of VEGF-A as well as the therapeutic efficacy of angiogenesis inhibitors in diabetic nephropathy have been reported.
|
21228103 |
2011 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pathway analysis highlighted the regulation of Ras homolog gene family member A, Cdc42, integrin, integrin-linked kinase, and vascular endothelial growth factor signaling in DKD glomeruli.
|
21752957 |
2011 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Soluble Flt-1 (sFlt-1) is the endogenous inhibitor of VEGF, and recently genetic overexpression of sFlt-1 in the podocyte was shown to be protective in murine diabetic nephropathy.
|
20015944 |
2010 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In diabetes, over-production of NO might play a role in the development of diabetic nephropathy, while reduced NO production may be related to the development of diabetic retinopathy and neuropathy, where VEGF (vascular endothelial growth factor) levels are increased in a counter regulatory manner.
|
20565248 |
2010 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) is a dimeric glycoprotein that plays a crucial role in microvascular complications of diabetes, including diabetic nephropathy.
|
20501654 |
2010 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HG also augmented VEGF expression, decreasing nephrin expression and podocyte number-a critical event for the development of proteinuria in diabetic nephropathy.
|
20522599 |
2010 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was no difference in VEGF genotype distribution between the control and diabetic patients based on the state of diabetic nephropathy and neuropathy.
|
19796028 |
2009 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, we have hypothesized that uncoupling of VEGF with endothelial NO can be a mechanism by which VEGF causes diabetic nephropathy.
|
18926584 |
2008 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
LHGDN |
Podocyte-derived vascular endothelial growth factor (VEGF), a permeability and angiogenic factor whose expression is also increased in animal models of diabetic kidney disease, appears to act in a novel autocrine signaling mode to induce the podocytopathy of diabetes, especially the genesis of albuminuria.
|
18842317 |
2008 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
CTD_human |
[Effects of valsartan on the renal vascular endothelial growth factor and its receptor flk-1 of diabetic rats].
|
18630688 |
2008 |